Ligand: Q4 Financial Results Overview

Ligand Pharmaceuticals Reports Strong Fourth Quarter Results

Ligand Pharmaceuticals Inc., based in Jupiter, Florida, announced a net profit of $44.8 million for the fourth quarter.

The company’s earnings translated to $2.12 per share, with adjusted earnings—excluding one-time gains—coming in at $2.02 per share.

These figures exceeded analysts’ expectations, as the consensus among four analysts polled by Zacks Investment Research had projected earnings of $1.46 per share.

During the quarter, Ligand generated $59.7 million in revenue, outperforming the anticipated $58.2 million estimated by analysts surveyed by Zacks.

For the full year, Ligand reported a total profit of $124.5 million, or $6.13 per share, on revenue of $268.1 million.

Looking ahead, the company forecasts annual earnings between $8 and $9 per share, with projected revenue ranging from $245 million to $285 million.